Oraliva

Principal Investigators: John McDevitt, PhD

OraLiva Inc. has developed a next-generation, programmable, single-cell cytology platform that is suitable for early cancer detection. This award-winning programmable platform has been adapted for oncology screening applications for use at the PoC and allows clinicians to see early signs of cancer using ‘cyto-signatures.’ OraLiva Inc’s proprietary “C-AIIDE” (Cytology Artificial Intelligence IDEntification) technology allows for multiparameter single-cell measurements to be completed in near real-time, using several cross-indication biomarkers to develop new variables in assessing various states of dysplasia, the precursor to malignant tumor/lesion/polyp development. The “lab-in-a-kit” and algorithm are designed to augment current diagnostic capabilities, including flow cytometry, tissue biopsy/histology, and lab-based manual cytology tests, which are less accurate and more costly to run per test.